Tumor Microenvironment

November 1st - 4th, 2018

Co-Chairs:
Rakesh K. Jain, Ph.D., Massachusetts General Hospital, Boston, MA
Lisa M. Coussens, Ph.D., Knight Cancer Institute, Beaverton, OR

Participants:
Peter Carmeliet, MD PhD, Center for Cancer Biology, Leuven, Belgium
David G. DeNardo, PhD, Washington University School of Medicine, St. Louis, MO
Stephanie K. Dougan, PhD, Dana-Farber Cancer Institute, Boston, MA
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Dai Fukumura MD, PhD, Massachusetts General Hospital, Boston, MA
Ronald N. Germain, MD, PhD, NIAID, National Institute of Health, Bethesda, MD
Richard O. Hynes, PhD, Koch Institute at MIT, Cambridge, MA
Elaine R. Mardis, PhD, Nationwide Children's Hospital, Columbus, OH
Daniela Quail, PhD, McGill University, Montréal, Québec
Andrea Schietinger, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Melodie Swartz, PhD, University of Chicago, Chicago, IL
David Tuveson, MD PhD, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Matthew Vander Heiden, MD PhD, Koch Institute at MIT, Cambridge, MA
Jennifer Wargo, MD, MD Anderson Cancer Center, Houston, TX
Irv Weissman, MD, Stanford University, Stanford, CA


Program Description

All cancers contain diverse populations of cells, including those harboring genetic mutations, aka "tumor" or "cancer" cells, as well as other "normal" cell types activated andor recruited to local tumor microenvironments. Both preclinical and clinical data indicate that components of the tumor microenvironment (e.g., blood and lymphatic vessels, fibroblasts and other mesenchymal support cells, innate and adaptive immune cells, as well as extracellular matrix, hypoxia, and low pH), while regulating hallmark features of cancer development, can also thwart efficacy of cytotoxic, targeted and new- age immune therapies. This Forbeck Foundation meeting will bring together existing and emerging thought leaders spanning the breadth of tumor microenvironment, immune- oncology and computational biology disciplines to discuss novel approaches to identify critical mechanisms regulating crosstalk between neoplastic and "host" cells, with an emphasis on those that subvert anti-tumor immunity. We will also discuss therapeutic approaches to target aspectscomponents of the tumor microenvironment that effectively liberate anti-cancer immunity for durable tumor control, how these strategies are being deployed in patients, and initial clinical findings.

The 2018 Forum on Tumor Microenvironment will be chaired by Dr. Rakesh K. Jain of Massachusetts General Hospital and Harvard Medical School, and Dr. Lisa M Coussens from the Knight Cancer Institute at Oregon Health & Science University. The goal will be not only to discuss the current state of the tumor microenvironment field, but also discuss approaches towards applying that knowledge to the development of effective and broadly applicable anti- cancer therapies for long-term management of disease.